Healthcare News 8

• "Agenda" designed to suit Genta's Agenda!!!
• "Doc I just take it as PRESCRIBED"!
• "I Told You So" says the Dr. to the Patient!
• "New kid in town"
• "The Big GLP" - Should We Be Excited About Novo's Liraglutide?
• ?Role of IMC-A12 for metastatic prostate cancer
• A 3-tiered healthcare system
• A BIG case of "conflicts of interest"
• A Classic Example of An Association Mistaken for a Cause
• A generic of EPO in Japan
• A long way to go
• A new agent to provide analgosedation in the ICU. Is it better- that remains to be seen!
• A new strategy in the treatment of malignant gliomas?
• A new typr of Uveitis treatment for 2008?
• A Novel Approach to Infection - No More Staph Meetings!
• A Novel Brain Tumor Therapy at Last
• A potential "breakthrough"
• A Quack Company is Caught By The FDA
• A Very Good News for Patietns and Physicians
• Abilify is Go to Drug for Adjunctive treatment for Depression
• About time to get rid of B&L management!
• ABT-335 and Crestor Combination Has Great Potential
• Access issues will be a prominent part of successful "health care reform"
• Actelion Has A Non-Sedative-Hypnotic Sleep Aid That Appears Effective and Safe
• ADHD Medications Not a Cure, But a Start for Dysfunctional Kids
• Advanced Medical Optic's CEO Blames Consumers, Not Complete MoisturePlus, For Increasing Risk of Parasitic Infection
• Agreement for further development and commercialization of inh amikacin
• Agreement to availability
• Allowing non-physicians to practice medicine
• Alot of smokers in the EU. Roche and Genentech will be happy +.......
• Alternative medications available
• ALZHEMED will have close FDA contact to speed the review of the drug for political reasons established by Congress.
• AM103 needs to be safer than Zafirkulast and Zileuton drugs that have not out lasted Montelukast
• AMA Masterfile to Pharma
• AMO overtakes Bausch and Lomb; Unlikely
• AMO takeover of B&L
• An alterior motive???
• An Exciting New Tool for Arrhythmia Management
• An ounce of prevention is worth a pound of cure.
• And What Pray G-D is Brain cancer?
• Angio-seal today-SS
• Another blow to DES
• Another Chiral Medication Without Significant Benefit
• Another Discontinued Potential Hepatitis C Treatment
• Another nasal corticosteroid
• Another need for LX211 treatment of uveitis?
• Another significant disappointment in the Fight against Hep C
• Anti eosinophil therapy for asthma offers new hope --- yet needs to be proven
• Antibodies in asthma
• Antidepressant, Weight-Loss Drug, and ADHD Treatment, all-in-one?
• anything new?
• AS 1411 for AML: Would it outperform Cloretazine??
• ASA404 - interesting results
• Asking for evidence based results
• Asthmatics respond
• At least another one to two years
• Ateempt at End Run Around Patent Expiration Will Likely Fail
• athletes have always risked their health, eyes included
• Availability of primary care physicians will only improve if the financial bottom line improves
• Avandia And The Story Of Humpty Dumpty
• Avandia, data, and PR damage
• Avexa and ATC - Will it make a difference?
• Azixa a Long Shot in Non-Small Cell Lung Cancer
• Baxter's IVIg in Alzheimer's Looks "Favorable;" Phase III Trial Announced
• Beating a horse to death
• Better or different vs: Byetta?
• Better stent technique
• Better?
• Between a Rock and a Hard Place
• BIBW 2992 I'm Impressed
• Bifeprunox another symptom of moving Research from Rouses Point NY to Pearl River NY
• Bifeprunox: A Drug Not Approved By The FDA Because It Lacks Efficacy
• Bifocal versus monovision.
• Bilateral Cataracts are Associated with Better Visual Outcomes than Unilaterl Cataracts in Children.
• Bimatoprost (AGN) may have better Pressure Control but Latanoprost (PFE) is still KING.
• Bimatoprost is known to be slighatly more potent that prostaglandin
• Biodem's (ASX:BDM) Subcutaneous Injection POTENTIAL Treatment for Diabetic Macular Edema.
• Biolinerx: Issues to Consider
• BioWa: between Yin and Yang
• Bipolar Disorder in Children: Higher Incidence or More Accurate Diagnosis
• BL-1020 the First Novel Antipsychotic in Quite a While
• BMS/Otsuka’s Abilify: New Target, Huge Market!
• Brachytherapy for inoperable pancreatic cancer: Promising, but very preliminary results
• Branded drugs have value in epilepsy, but future is unclear
• Branded drugs have value in epilepsy, but future is unclear
• Bringing up old concerns
• Bristol-Myers Diabetes Drug, A Novel Mechanism, A Long Road To Haul
• Bristol-Myers Squibb(BMY) Has Another Winner with sNDA for Depression(?)
• Build it and they will come (or not)
• Bureaucracy, More Fed, Less Fed or Just Fed-Up?
• Bush administraton prioritizes health plans over nation's health
• California Docs do Better with Health IT: Is it a Chicken or Egg Phenomenon?
• California—A Huge Health Care Battle of its Own With National Significance as the Governor and the Legislature Get ready to Hammer Out Health Care Reform
• Campaign against switching to inexpensive generics epilepsy pills
• Can Medical Insurers Survive Based on Old Methods of Profitability?
• Carrots and sticks to improve patient safety.
• Cervical Artificial Discs - What will it add to the bottom line?
• Changes in Long Term Care Leadership Significant
• Changing the supply and demand curve for primary care
• Cheap broadband connectivity and ubiquitous powerful computers provide the opportunity to improve Medical Care everywhere.
• Cheaper AIDS Drugs and Future Development
• China's albumin shortage creates a major shock
• Chronic disease is a leading cause of our rising health care costs
• Chronic diseases have been around for centuries, our tools need to evolve, now. by L Dawson,Dipl.Ac., L.Ac. Food Physics &Body Dynamics LLC
• Cigna covers lumbar disc replacement
• Cis, Carbo, Oxal... Do We Need Another Platin?? You Bet If It Works
• Classic HMOs improved Quality while decreasing cost-their loss is societies and physicians
• Clobutinol banned -- the question isn't why, it's why so long?
• CMS
• CMS Decision to withold hospital payments for hospital errors; it's about time
• CMS policies - Not what the doctor ordered
• CMS regulations penalize hospitals for taking care of sickest patients
• CMS rules will reduce ESA's use dramatically
• Coffee preventing cancer?
• Combination therapy for dyslipidemia - the next big thing
• Competing against AIMHIGH
• COMPLETE® MPS Easy Rub™ Formula....Whats the active ingredient?
• Compliance with pharmacotherapy in the Type II / Metabolic Syndrome Patient
• Concierge Medicine : The underlying benefit
• Concierge medicine raises many questions
• Concierge or Snobs
• Consumer Driven Health Care: Elasticity of Demand and the Supply of Primary Care Physicians (Health Economics Consulting Group, LLC, at www.hecg-llc.com)
• Consumer engagement in the financing of health care is necessary, but not medical decision making
• Co-payments, prescription use, and consumer-directed health plans
• cost and reimbursement
• Coumadin Senstivity Testing Controversial
• Counter-productive reaction to ragweed, fruits and vegetables intake
• CSL Behring's Liquid IVIg Ramps Up the Competition
• Curbing Chronic Disease Means Confronting Under-funding of Behavioral Health Care.
• Current Medicare policy rewards mediocre/poor care to Americans
• Custom laser able to deliver monovision.
• CVS' Growing Channel Power
• CVS/Pharmacy stores for medical basic assistence.
• Daptomycin approved in Europe for MRSA bacteremia and right sided endocarditis
• Death of our Profession
• Diabetes Medications Are For Sugars; Statins and Hypertensives Are For Hearts
• Diagnostic Systems Serve as Physician Memory Boosters
• Diversion from Canada via China
• Do not lose heart--it causes weight loss
• Do PPIs Increase the Risk of Cardiovascular Disease? Probably Not
• Does Eyeonics have a long term future
• Does not change anything
• Does the FDA have an impaired "cerebro-verbal" filtering mechanism?
• Does this mean we should use PPI's instead?
• Don't stop your statins now...
• Don't stop your statins now...
• DOV 21,947: Is The Antidepressant That We Have Been Waiting For?
• Dov Pharmaceuticals (DOVP.PK) May be a Winner, but it is Too Soon to Get Hopes Up
• Drug & Device Disclosures Could Be Painful to Some Physicians
• Drug Could Be A Blockbuster
• dupuytrens contracture
• Early Detection on Active Cancer Metastatsis to Curing Cancer
• Ease of use
• Elective Cosmetic procedures
• Eligard® for Prostate Cancer wins EU approval
• Encouraging results for a oral preparation in a terminal disease from an excellent center
• ERBITUX
• ERBITUX
• Erbitux is far from over in Colorectal Cancer
• Erbitux/Bristol- Where is the Beef?
• Erythropoetin, a Window Open?
• Erythropoietin Fails to Reduce Transfusion Needs in Critically Ill Patients
• ESA
• ESA use guidelines are fair and may lead to lower prices
• Etoricoxib: Cox-2 inhibitors and Merck
• Evolution: Trial design NOT rational
• Excellent News — Global Sales Implications Iomai Corporation reduces E. coli infection
• Expect more "good" clinical news from this new class of antihypertensives
• Expect These Restrictions to Spread to Most of The World
• Eyelid basal cell carcinoma
• Eyeonics Going Public
• FDA Approval of Sanctura XR, good news or ho hum?
• FDA issues warning to Melanocorp
• FDA Review of Proton Pump Inhibitors (PPI's)
• FDA sticks to it's guns
• Fenofibrate and dyslipidemia ABB
• Fight over Medicare cuts ignore patients-as usual!
• First step in the right direction
• Gambling for surgery abroad - cheap option?
• Genetics of RA
• GlaxoSmithKline adds a Black Box Warning for Avandia.
• GLP-1 ANALOGUES AND DPP4 INHIBITORS
• Good device but not much improvement.
• Good News: First Generic Versions of Coreg is Approved
• Good trial!
• GRAVITY study
• Great technology, but there is competition
• Great, But.......
• Growing Pains
• Growth factor use
• GSK bashes RFID but quickly recants
• GSK gets a FDA non approval letter for Advair and it's use in COPD
• gsk market analysis
• GSK's Rotarix: Another good vaccine product beaten to the punch by Merck
• Guilt by association
• Hand washing effect not a surprise
• Haven't physicians been lending "no-interest" money to payers and patients all along?
• Health Insurers lighting a fuse on their own destruction
• Health IT, Transparency and Quality Based Financial Incentives Score the Trifecta
• Healthcare: Medicare to cut funds for error prone hospitals
• Hello, I'm here to sell you Allegra D, and Xyzal, but not Allegra or Zyrtec!
• High Density Silicone Oil may be Useful in Complex Retinal Surgery.
• HMOs Will Likely Sustain Payment Cuts to Their Private Medicare Business
• How much will it cost and for how long?
• Hydrocodone -- The Return of Hill Billy Heroin?
• I wouldn't expect a jackpot
• Ibuprofen for CF: Tepid results with sensational coverage
• If 10% cut to Physicians occurs, Medicare HMO's will be gone
• Impact of new Medicare Regulations on reduction of hospital infections and medical errors
• In the long run, cervical disc replacement will likely gain the acceptance of most insurers
• Innovation, but is it safe
• Innovation? Not really, just an attempt to make money off of patients!
• Innovative Medical Financing Options will Continue to Grow Even Beyond Elective Procedures
• Innovative Ultrasound Application
• Insurers must think out of the box to improve profitability
• Integrase Inhibitor a Welcome Addition for Treating HIV
• Interesting Collaboration with potential but competition is already there
• Interesting trial but let's look at the non-investigational drug
• Interesting Vaccine, But Study Left Out a Lot of Important Information
• Interesting! Pancreatic Cancer Needs Another Break!
• Interesting, but too early to tell
• Is it less or more cancer with statins?
• Is it the sugar in soft drinks that we should be concerned about?
• Is the recent Contact Lens Infection Outbreak the fault of AMO or Poor Hygiene?
• Is the steriod dose the concern
• It is a matter of Change in Physicians' Behavior
• It's better to be paid something than nothing
• I've used it and it works, but...
• Ixabepilone is likely to be a Biggy in NSCLCa
• J&J's civil complaint against Red Cross to net positive for J&J?
• Johnson & Johnson follows industry's job-slashing trend
• Johnson & Johnson Needs New Pharmaceutal Products (aka New Chemical Entities)
• Johnson & Johnson take the American Red Cross to task for focusing on increasing income
• JSM 6427: the new face of armd therapy
• Junk Science
• Kaiser has problems (and has proposed reforms) with its quality assurance programs.
• Keep Drinking Soft Drinks, and Keep the Diabetes Industry Alive!
• Keep Your Eye On This Drug, But it is Not Clinically Proven Yet
• Knee Jerk Reactions to FDA advisories Harm Patients Maybe More than Potential Adverse Drug Effects
• Know what is in your Medical Record or You May Pay or Be Uninsurable
• Known to allergists, but perhaps not to the rest of the medical community
• Kudos to the FDA!
• Kyphon products are complimentary to Medtronic offerings
• Laropiprant no better than aspirin? or is it?!
• Lasers for Spider Vein (Phlebectasia) Treatment are Good Enough
• Let's Get Real HMO's
• Let's see what the Phase III shows
• Liraglutide is a small step forward, but there will be bigger steps to come shortly.
• Liraglutide, potenital, and barriers
• Long term weight loss measured in 24 weeks?
• Looking forward to Vical Phase 1 Trial of H5N1
• Lung Cancer Junkies take note!
• LX211 (LUX) could be a Blockbuster Drug in the Treatment of Uveitis.
• LX211 (LUX) could be a Blockbuster Drug in Uveitis Management.
• LY2140023: An Antipsychotic With A New Mechanism of Action
• Major Implications for Patients, Doctors, Insurers,Laboratories & Malpractice Attorneys
• Major Step for Personalized Medicine: Warfarin Sensitivity DNA Test Required By FDA
• Managed Medicaid: A Good Idea or a Recipe for Disaster?
• Managing Chronic Diseases is the Key to Bending the Trend of Our Growing Healthcare Expenditures or is it?
• Market forces and health care are mutually exclusive
• May become drug of choice for the lipid abnormalities in the metabolic syndrome and diabetes
• May fill a definite need!
• Maybe cheaper isn't better.
• Medical Globalisation, Let The Games Begin
• Medical Tourism
• Medical Tourism -- Bargain or Boondoggle?
• Medical tourism out of patients' desperation
• Medical tourism is here to stay
• Medical tourism will continue to flourish
• Medicare Advantage Plans are only an advantage for the Insurance Industry.
• Medicare Continues Assault on Healthcare Reimbursement
• Medicare cutbacks will result in lack of options for patients in small communities
• Medicare should NOT pay for errors-but what are "errors"
• Medicare's attempt to shift cost to private sector.
• Medicine or banking- what will you practice?
• Medtronic is one step closer to finalize study of deep brain stimulation for epilepsy
• Medtronic's acquisition of Breakaway Imaging is a significant step forward
• Merck to challenge Abbot and Pfizer in cholesterol market
• Might BIOLINERX hold the next major class of antipsychotic medication?
• Millenium EVOLVE Trial Not True Evolution
• Minute Clinic addresses some drawbacks of clinic-in-a-box
• Mircera: Roche vs Amgen (with the FDA looking in)
• Mitiglinide—Thrice Your Out
• MKC-1
• Monovision versus Multifocals
• Monovision WILL NOT solve the Presbyopia problem.
• More bad news for community pharmacies.
• More bad news for J&J
• More results on ASA404
• More trouble for gene therapy
• Move over Velcade
• Multidetector CT technology will replace conventional angiography
• Multivarient antibiotic resistance research
• Nationwide availability of Shire's new ADHD medication -VYVANSE (lisdexamfetamine dimesylate)
• Neat idea, needs to be tested.
• Need to meet your primary endpoints.
• New afterloader maybe not a bad idea for starting an HDR program
• New breast radiation fractionation not standard
• New breath of air for iressa
• New Class of Antipsychotic Agents
• New contact lens solution or Complete redux?
• New Era for Pharmaceutical Industry
• New Medicare guidelines punish side-effects of therapy, not treatment errors
• New medicare regulations by the CMS to reduce hospital acquired infections
• New medicare regulations to force hospitals to do more with less
• New MS treatments to be based on genetic breakthrough?
• New Myasthenia Treatment Makes Sense
• New platinum agents are needed
• New Potentially Effective Antidepressants to be Marketed by a Potentially Effective Alliance
• New tricks for an old dog
• News watch - Imclone Systems New Appointment
• Nexavar (sorafenib) phase III trial absolutely demonstrates a modest clinical benefit
• Nimotuzab : A"proof of Principle" trial
• Nimotuzab for brain gliomas: Key role will be in combination therapy
• Nimotuzumab holds promise for glioma patients
• No Brainer
• No Interest in Medical care? Or the Greatest Interest in Medical Care.
• No Interest Loan Utilization in Dental Practices Eases the Pain
• No major benefits from dextromethorphan and pseudoephedrine.
• No More Enabling Pharmacists?
• No Pay for No Performance?
• No proof that new combination pill for high triglycerides and cholesterol improves outcomes
• No surprise
• Noble Ideals Must Be Backed By Money
• Non-Medical Opinion About Medical Issues
• Not a bad idea, but some are going to be upset....
• Not a Surprise But Great News!
• Not a surprise! The HIF 1 alpha stabilizers, not EPO, is the answer
• Not All Statins Are Born The Same!!
• not always
• Not Going to Take off Anytime Soon
• Not so surprising
• Not unexpected
• Nothing new
• Novartis Epoetin (Epo). Impact??
• Novartis extends it's cardiovascular arsenal.
• Novation is an asset as newly acquired by General Electric Company
• Novel approach
• Novel Experimental Approach to Gliomas
• Novel Oral Tablet Option For the treatment of Bone Diseases
• Omrix' Thrombin Is Out of the Gate Ahead of ZymoGenetics
• Only results and a relatively short time will tell
• Oral agent for prostate cancer: rational design, but have to wait for results
• Outsourcing is part of business dynamics
• Overblown press on Drug Importation
• Pain sensationalism again in an election year
• Patient Heal Thyself
• Patients are liekly to like oral better than IV
• Pay for performance at work
• Pay for Performance Needs a Rosetta Stone to Keep Going
• Pediatric Bipolar Disorder is an Urgent Public Health Problem
• Pedigree and Presidential Politics
• Per Quest, commonly used technology for the assay.
• Pharmaceuticals - Explanation of Genetic Toxicology Evaluations
• Phase 2 that will give phase 3 like results. Good trial
• Physicians will have to look in the mirror to solve America's medical cost inflation
• Poniard's Picoplatin- a success?
• Potential Market for this Vaccine is Huge
• Potentially Great Study!!
• Preliminary Rate of Response 14%, Goal 15% Pediatric Brain Cancer-Reachable
• Price cuts to physicians equals increased pay to adminstrators and investors
• Primary care physicians--look to your "friends" for your professional salvation
• Priority Review for ABILIFY(R) (aripiprazole) as adjunctive to antidepressant therapy (ADT)
• PRISTIQ(TM) (desvenlafaxine) of Wyeth can be expected to be on the market soon for Vasomotor Symptoms Associated with Menopause.
• Pristiq--will it really be hot for hot flashes?
• Professional Boxer's Career In Jeopardy Because of Poor Contact Lens Hygiene
• Profound Clinical Impact of Sugammadex for the Modern Anesthesiologist
• Promising Vaccine Targeted Towards Wrong Market and Wrong Immune System
• Promising, but too early to tell
• Ranbaxy's carvedilol could provide relief to both patients and their payors
• Rational drug development is refreshing
• Reality Check on AMP's Impact
• Rebooting: the Immune system is not a PC
• Remember, this is topical......
• Retail drugstore clinics - filling a niche ?
• Retail medical clinics are a welcomed addition to our current medical delivery model
• Revlimid for MM: Switzerland is following the US and EU trends
• Safety for Patients and Physicians with Electronic Presriptions
• Sanctura XR Approval : Too late in a Crowded Market
• SCHIP Eligibility is a Battle but not a Central Part of the Health Care War
• Scrutiny of OTC cough and cold remedies are long overdue, though insufficient
• Sepracor(SEPR) Expands its Lunesta Reach, But Let's Not Count Out Indiplon from Neurocrine(NBIX)
• Sharpe Rise of Opioid Drugs Abuse in United State
• Shire (SHPGY) May Have Another Winner, But This Will Take Some Convincing
• Shortage of Rural Doctors - The U.S. Can Learn From Canada
• Should have lauched this first!
• Shouldn't be a big issue to achieve reimbursement
• Siemens to acquire Dade behring
• Simple, straightforward, and possibly clinically useful.
• skimming the creme
• SMALL STEP FORWARD IN ALZHEIMER'S TREATMENT
• Smart move
• Smart Move
• Some Clinical Observations on Shire's Vyvanse
• Some Contact Lens Patients Still Unaware of AMO's Complete MoisturePlus Recall
• Some of my best friends are concierge physicians
• Source important
• South Carolina's Move to Managed Care is Behind other States
• Speech Recognition Importance to practicing Radiologists
• Speech Recognition in it's Adolescence
• Speech Recognition Software Improves Efficiency
• State Medicaid Formulary Committees and Potential Conflicts of Interest - Pharmaceutical Companies and Physician Relationships
• Stents: Acute and late thrombosis; restenosis
• Steroids + Calcitonin = New therapy?
• Stimuvax looks more than just promising
• Strange happenings at Bausch & Lomb
• studies of low back pain therapy lead to mixed findings
• Subcutaneous injections as treatment for diabetic retinopathy would revolutionize care for these patients
• Surgery for spondylolisthesis is better than non-operative treatment
• Surgey Abroad is More Than a Fad ...For Now
• Surgical procedures NOT the future - minimally invasive procedures ARE future
• SYMLIN-All this poken' could lead to one smoken'
• TEARS OF THE RETINAL PIGMENT EPITHELIUM: An Old Problem in a New Era.
• The American Red Cross has lost its senses. Players who joined will back out as Johnson & Johnson's action against them is not worth the risk.
• The beginning of the end?
• THe CMS uses ESAs to start restricting cancer care
• The drug patent "shell game"
• The Fallout from HD Supply
• The Good News Is....
• The Missing Links from Michael Moore's Magic Pills for Health Care
• The more things change the more they stay the same--enough already!
• The Move of All Government Managed Health Care to Managed Care Organization
• The New Medicare Regulations: Realistic or The Beginning of a Witch Hunt
• The Next Microsoft
• The Other Shoe Falls......
• the problem with health insurance
• The Targeted Genetics (TGEN) HIV Vaccine: Too little information to predict its future
• The Tooth Fairy - A Fairy Tale about a Tooth Filled Drug Delivery System
• The ultimate personal physician - a growing trend
• The Vast Potential for High Energy Ultrasound
• The wave of the future
• There is always room for new agents in lung cancer
• They have improved, but they are not the holy grail
• Third-party payers using ASP today. Is AMP next?
• This coud ne a Panora's Box
• This is potentially a real advance in treatment of neuropsychiatric disorders
• This Sounds Like A Winner
• Tibotec Pharmaceuticals Ltd. NDA for TMC125 etravirine is on the FDA "Fast Track" and should not be.
• To Err is Human-to forgive? not medicare.
• To reconstruct or not reconstruct
• Tomotherapy (ttpy) enters mainstream
• Too early
• Too early to tell
• Too early to tell
• Too little too late
• Topical treatment for metastatic disease....not likely
• Tout a technological advance while mired in older work-flow
• Trial Proved Drug Not Effective
• Trouble before it starts?
• TVT- A MINIMALLY- INVASIVE DISAPPOINTMENT
• Two for One
• Ultrashape - good first attempt
• Ultrashape body contouring: Another arrow in the noninvasive quiver
• Ultrashape is VERY Innovative, and Looks Very Promising
• Unfortunate, but a rising reality
• Unintended costs of medical excellence and medical advances
• Uracil-tegafur When You Have a Hammer Everything Looks Like a Nail
• Vasomotor symptoms associated with menopause-approval from the FDA
• VEGF trap
• VEGF Trap (RGN, BAY) may give Lucentis (DNA) some competition in the AMD Market.
• VEGF Trap Makes Progress for Wet AMD
• Vertebroplasty vs kyphoplasty vs arcuoplasty
• Vyvanse: Pros and cons
• wanning immunity as a future public health issue
• Warning Makes No Sense
• Watson Pharma to India: If you can't beat 'em, join 'em
• We have the data, but will it change behavior?
• welcome to the future
• What a surprise - another way for CMS to save money
• What are the Alternatives?
• What are the potential ramification for Avandia following the FDA Advisory Committee?
• What are we to do?
• What is the TASQ in managing prostate cancer?
• where does this fit into the treatment algorithm?
• Where's the data??
• Who cares about another "new" Triglide?
• Who Knows # 19 (I think I do)
• Who Knows #17
• Who Knows #18 (with a bullet)
• Wholesaler Investment Buying Still Matters
• Why do we believe that cholesterol lowering is beneficial?
• Why not?
• Will Bausch & Lomb (BOL) Accept AMO's (EYE) Better Bid?
• Will combination therapy be better in hormone refractory prostate cancer?
• Will HMOs See Significant Cuts in Their Private Medicare Payments?
• Will Medicare patients become the chess piece to improve hospital care?
• Wise Investment: Only time will tell!!!
• Would Coffee Enemas Work in Men??
• Wyeth’s Bifeprunox Bites the Dust
• Wyeth’s Bufeprunox –Still Some Hope Here?
• Wyeth’s Pristiq: Gone with the Wind
• Xiaflex will dramatically replace surgery
• Xyzal approval
• Xyzal is a more or less unnecessary drug being added to a saturated market
• Xyzal: wait and watch before adoption.
• Yes and no - balance fighting the tumor vs. triggering uncontrolled inflammation.
• Yet Another Example of Why Physicians Should Wait to Prescribe New Drugs
• YM BioSciences glioma treatment studies are difficult to design and measure
• You bet!
• You mean to tell me......?